Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

KITE PHARMA, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2009-01-01

Employees: 1K

Market Cap: -

Website: http://www.kitepharma.com

Clinical Trials

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Phase 3

Active, not recruiting

Conditions: Relapsed/Refractory Follicular Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine

First Posted Date: 2022-05-12

Last Posted Date: 2025-05-09

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 230

Registration Number: NCT05371093

Locations: 🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸
Stanford Health Care, Stanford, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 49 locations

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Phase 2

Conditions: Solid and Hematological Malignancies

Interventions: Biological: Brexucabtagene Autoleucel
Biological: Axicabtagene Ciloleucel
Biological: Anitocabtagene autleucel
Biological: KITE-753
Biological: KITE-197
Biological: KITE-363

First Posted Date: 2021-09-13

Last Posted Date: 2025-06-18

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 1000

Registration Number: NCT05041309

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 80 locations

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Phase 1

Recruiting

Conditions: Relapsed and/or Refractory B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: KITE-363
Biological: KITE-753

First Posted Date: 2021-08-04

Last Posted Date: 2025-05-25

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 114

Registration Number: NCT04989803

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States

and more 11 locations

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Brexucabtagene autoleucel

First Posted Date: 2021-05-10

Last Posted Date: 2025-01-23

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 90

Registration Number: NCT04880434

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
University California Los Angeles (UCLA), Santa Monica, California, United States

and more 37 locations

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: KITE-222

First Posted Date: 2021-03-09

Last Posted Date: 2024-06-10

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 15

Registration Number: NCT04789408

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Lenzilumab
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-03-19

Last Posted Date: 2024-03-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 6

Registration Number: NCT04314843

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States

and more 7 locations

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Conditions: Relapse/Refractory Mantle Cell Lymphoma

First Posted Date: 2019-11-14

Last Posted Date: 2021-10-14

Lead Sponsor: Kite, A Gilead Company

Registration Number: NCT04162756

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: anitocabtagene-autoleucel

First Posted Date: 2019-11-07

Last Posted Date: 2024-07-17

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 40

Registration Number: NCT04155749

Locations: 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer
Multiple Myeloma
Ovarian Cancer
Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer
Fallopian Tube Cancer

Interventions: Biological: CART-TnMUC1
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-07-18

Last Posted Date: 2024-01-24

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 16

Registration Number: NCT04025216

Locations: 🇺🇸
Mayo Clinic of Arizona, Phoenix, Arizona, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-28

Last Posted Date: 2024-02-20

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 27

Registration Number: NCT04002401

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy